Molecular imaging for neuroendocrine tumours.

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Molecular imaging is increasingly utilized in oncology for precise tumor localization and staging.
• Hybrid imaging, combining molecular and morphological techniques (e.g., PET/CT), significantly improves diagnostic accuracy.
• Receptor-targeted imaging has emerged as a key tool in diagnosing and managing neuroendocrine tumors (NETs).

Purpose of the Study:

• To review the current applications and advancements in molecular imaging for oncology.
• To highlight the role of somatostatin receptor imaging in well-differentiated neuroendocrine tumors.
• To discuss the limitations of current imaging modalities and the development of novel agents for NETs.

Main Methods:

• Review of current literature on molecular imaging in oncology, focusing on neuroendocrine tumors.
• Analysis of the diagnostic utility of somatostatin receptor imaging, 18F-FDG PET/CT, and DOPA PET/CT.
• Exploration of emerging imaging agents, including radiolabeled somatostatin receptor antagonists and GLP-1 receptor agonists.

Main Results:

• Somatostatin receptor imaging is crucial for well-differentiated neuroendocrine tumors.
• 18F-FDG PET/CT and DOPA PET/CT are vital for poorly differentiated neuroendocrine tumors and medullary thyroid carcinoma.
• Novel imaging agents are being developed to overcome limitations and expand imaging capabilities for all NET types.

Conclusions:

• Molecular imaging, particularly receptor-targeted approaches, plays a pivotal role in the diagnosis and management of neuroendocrine tumors.
• Advancements in imaging agents are crucial for addressing the limitations of existing techniques and improving patient outcomes.
• The review provides a comprehensive overview of the state-of-the-art in molecular imaging for oncology.